Current treatment practice and outcomes. Report of the hyponatremia registry.

Current management practices for hyponatremia (HN) are incompletely understood. The HN Registry has recorded diagnostic measures, utilization, efficacy, and outcomes of therapy for eu- or hypervolemic HN. To better understand current practices, we analyzed data from 3087 adjudicated adult patients in the registry with serum sodium concentration of 130 mEq/l or less from 225 sites in the United States and European Union. Common initial monotherapy treatments were fluid restriction (35%), administration of isotonic (15%) or hypertonic saline (2%), and tolvaptan (5%); 17% received no active agent. Median (interquartile range) mEq/l serum sodium increases during the first day were as follows: no treatment, 1.0 (0.0-4.0); fluid restriction, 2.0 (0.0-4.0); isotonic saline, 3.0 (0.0-5.0); hypertonic saline, 5.0 (1.0-9.0); and tolvaptan, 4.0 (2.0-9.0). Adjusting for initial serum sodium concentration with logistic regression, the relative likelihoods for correction by 5 mEq/l or more (referent, fluid restriction) were 1.60 for hypertonic saline and 2.55 for tolvaptan. At discharge, serum sodium concentration was under 135 mEq/l in 78% of patients and 130 mEq/l or less in 49%. Overly rapid correction occurred in 7.9%. Thus, initial HN treatment often uses maneuvers of limited efficacy. Despite an association with poor outcomes and availability of effective therapy, most patients with HN are discharged from hospital still hyponatremic. Studies to assess short- and long-term benefits of correction of HN with effective therapies are needed.

Acromegaly: a new therapy.

BACKGROUND: The treatment of acromegaly can be challenging. Despite a multimodality approach (surgery,radiation, dopamine agonists, somatostatin analogs), many patients do not achieve normalization of serum insulin-like growth factor I (IGF-I) concentrations. METHODS: The author discusses the characteristics and indications of pegvisomant therapy for patients with acromegaly and compares the use of this newly developed GH receptor antagonist with other pharmacological agents such as somatostatin and dopamine agonists. RESULTS: Therapy with pegvisomant allows serum IGF-I concentrations to be normalized in up to 97% of patients with acromegaly, including those who have failed other treatment modalities. With this agent,circulating GH levels increase as a result of the drop in IGF-I levels. The rise is rapid (within 2 weeks) and does not appear to be progressive over time. CONCLUSIONS: Published studies have shown pegvisomant to have efficacy in the treatment of acromegaly. As it appears to be well tolerated and safe, this novel compound may be an important therapeutic option for patients with acromegaly. Additional study of this novel agent and its mode of action is warranted.

Frameless stereotactic navigation in transsphenoidal surgery: comparison with fluoroscopy.

Surgical navigation systems (frameless stereotaxy) have been used in addition to or instead of fluoroscopy during transsphenoidal surgery. This study compares the intraoperative localization by an optical tracking system (Elekta Viewscope) with fluoroscopy. Viewscope and fluoroscope sagittal images were compared by the establishment of a Cartesian coordinate system based on anatomical landmarks and by the spatial localization of surgically relevant points for 20 patients. The Viewscope was found to have a total deviation of 3.0 +/- 0.6 mm (mean +/- SD) compared to fluoroscopy (p < 0.01). Much of the error resulted from the registration process, which according to the Viewscope software had an expected error of 3.1 +/- 0.8 mm for this series of patients, and from the probe-to-system correlation (error of 1.0 +/- 0.3 mm). Although frameless stereotactic systems give the surgeon useful trajectory data with three-dimensional visualizations, they remain somewhat inaccurate. The multiplanar abilities of the Viewscope provide an additional but not mandatory advantage to the simplicity and accuracy of fluoroscopy during this type of surgery.